Full text is available at the source.
Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes
Comparing weekly diabetes medicines on blood sugar control and weight over 6 months in type 2 diabetes patients
AI simplified
Abstract
Among 2465 patients with type 2 diabetes, the overall mean change in glycated haemoglobin (HbA1c) was -0.5% at 6 months.
- The mean baseline HbA1c was similar for exenatide once weekly (8.3%) and dulaglutide (8.5%), but higher for albiglutide (8.7%).
- Weight change after 6 months was -1.4 kg for exenatide and -1.6 kg for albiglutide, while dulaglutide showed a greater change of -2.7 kg.
- All treatment options significantly reduced HbA1c levels, with no significant differences in effectiveness observed among the medications.
- Similar outcomes were seen in insulin-naive patients with baseline HbA1c levels of 7.0% or higher, and also for those with levels of 9.0% or higher.
AI simplified